DSM to make new EPI treatment for Mayoly Spindler
This article was originally published in Scrip
Executive Summary
DSM BioSolutions has entered into an agreement with the privately owned French pharmaceutical company Laboratoires Mayoly Spindler to manufacture its new treatment for exocrine pancreatic insufficiency (EPI), MS1819 lipase. Financial terms have not been disclosed.